Eastman Chemical Co

Eastman Chemical maintains a leveraged capital structure with total debt of $5.22 billion against $6.01 billion in equity, resulting in a debt-to-equity ratio of 0.87. The company holds $566 million in cash and equivalents, yielding a current ratio of 1.47, which supports medium liquidity risk. Operating cash flow turned negative at -$137 million in Q1 2026, driven by free cash flow outflows of -$240 million despite $103 million in capital expenditures. The balance sheet reflects total assets of $15.22 billion and total liabilities of $9.14 billion, indicating significant fixed asset investment typical of the chemical manufacturing sector.

Profitability metrics show a return on equity of 7.89% and return on assets of 3.11% for the latest period. Gross profit stood at $431 million on $2.18 billion in revenue, implying a gross margin of approximately 19.8%. Net income was $107 million in Q1 2026, down from higher levels in prior periods, reflecting margin pressure in commodity chemical segments. The valuation snapshot indicates a price-to-earnings ratio of 17.0 and a price-to-book ratio of 5.45, suggesting the market prices in future recovery potential despite current earnings compression.

Revenue is diversified across four operating segments: Advanced Materials, Additives & Functional Products, Chemical Intermediates, and Fibers. In Q1 2026, Additives & Functional Products generated $739 million, Advanced Materials $715 million, Chemical Intermediates $495 million, and Fibers $225 million. Geographically, sales are spread across Asia Pacific (36%), United States and Canada (33%), Europe, Middle East, and Africa (25%), and Latin America (6%) based on 2025 annual data. This geographic mix exposes the company to global economic cycles and trade dynamics, particularly in the Asia Pacific region which represents the largest single market.

The growth trajectory shows a decline in annual revenue from $9.36 billion in 2024 to $8.74 billion in 2025, a decrease of approximately 6.6%. Q1 2026 revenue of $2.18 billion represents a year-over-year decline from $2.29 billion in Q1 2025. Adjusted EBIT for the total operating segments fell from $364 million in Q1 2025 to $238 million in Q1 2026, highlighting significant earnings volatility. The Chemical Intermediates segment reported negative adjusted EBIT of -$18 million in Q1 2026, compared to $19 million in the prior year quarter, indicating severe margin contraction in this commodity-heavy division.

Risk factors include medium liquidity risk and low dilution risk, with key flags noting negative net cash after subtracting total debt. The company faces exposure to raw material and energy price volatility, global trade disruptions, and potential impacts from tariffs and geopolitical conflicts. Asset impairments and restructuring charges of $9 million in Q1 2026 further complicate the earnings profile, alongside net interest expenses of $52 million. The negative operating cash flow in Q1 2026 raises concerns about short-term liquidity management amidst high debt service requirements.

Recent events include an 8-K filing with material item 2.02, indicating significant corporate developments or financial results disclosures. Analyst sentiment remains cautiously optimistic with a mean price target of $80.37 and a median of $79.50, above the current market price of $70.07. The mean recommendation of 2.17 suggests a moderate buy rating, with 5 strong buys and 5 buys against 8 holds. Filing observations note partial coverage backfilling for cash and shares outstanding, ensuring data integrity for the latest period.

Eastman Chemical Co (EMN) has entered the analysis scope for the first time, establishing a baseline for future monitoring with no prior data available for delta computation. This initial snapshot captures the company's current structural profile, which includes a shareholder base comprising 34 top holders, while specific metrics regarding officer count, analyst coverage, and index membership remain unrecorded in this initial assessment. The most significant activity detected involves a major modification in the holdings of investor ID 587 as of March 31, 2026. Data signals indicate a substantial shift in this investor's position, with share counts fluctuating between 610 shares and 120,899 shares. These changes were detected on June 23 and June 24, 2026, reflecting a notable adjustment in the investor's stake during this reporting period. The financial impact of these holding changes is evident in the valuation metrics associated with investor ID 587. The value of the position shifted between $0.046 million and $9.227 million, corresponding to a weight percentage that varied from approximately 0.000027% to 0.0053% of the total. This volatility in a single holder's position underscores the dynamic nature of the shareholder base captured in this initial review. As this is the first analysis for EMN, these findings serve as the foundational reference point for tracking future material changes. The absence of prior basis for delta computation means that subsequent updates will be measured against this current state, including the specific holder activities and the established count of 34 top holders. No cross-source signals or sagas were identified to provide additional context to these initial observations.

Analysts project 19.2% upside to a mean price target of $81.24, reflecting a consensus buy recommendation from 18 analysts.

Cash conversion of 2.05 significantly exceeds the cohort median of 0.66, placing Eastman in the top quartile for efficiency.

Free cash flow reached $688 million in FY2024, demonstrating strong liquidity generation despite fluctuating revenue trends.

Net income grew 90.9% year-over-year to $905 million in FY2024, indicating significant profitability improvement.

Dilution risk is assessed as low, suggesting stable equity structure and protection for existing shareholder value.

Debt-to-equity ratio of 0.87 places Eastman in the bottom quartile of its cohort, signaling higher financial leverage risk.

Liquidity risk is rated as medium, highlighting potential constraints in meeting short-term obligations compared to lower-risk peers.

Revenue $2.18B; Net margin 4.9%.

• ▍Revenue $2.18B
• ▍Net margin 4.9%

Revenue $6.78B; Net margin 5.4%.

• ▍Revenue $6.78B
• ▍Net margin 5.4%

Revenue $4.58B; Net margin 7.0%.

• ▍Revenue $4.58B
• ▍Net margin 7.0%

Revenue $8.75B; Net margin 5.4%.

• ▍Revenue $8.75B
• ▍Net margin 5.4%

Revenue $9.38B; Net margin 9.6%.

• ▍Revenue $9.38B
• ▍Net margin 9.6%

Revenue $9.38B; Net margin 9.6%.

• ▍Revenue $9.38B
• ▍Net margin 9.6%

Revenue $9.21B; Net margin 9.7%.

• ▍Revenue $9.21B
• ▍Net margin 9.7%

Revenue $9.21B; Net margin 9.7%.

• ▍Revenue $9.21B
• ▍Net margin 9.7%